Abstract: Compositions and methods are described for oral treatment of gastric cancer. A composition of matter for treatment of gastric cancer includes navitoclax; and Bcl2 siRNA. The composition can include ?-glucan and docosahexaenoic acid as a mucoadhesive nanocarrier.

Abstract: Compositions and methods are described for oral treatment of stomach cancer. A composition of matter for treatment of stomach cancer includes fluoreuracil-5; and Bcl2 siRNA. The composition can include ?-glucan as a mucoadhesive nanocarrier.

Abstract: Treating solid tumors includes administering to a mammal in need of treatment a compound including at least one BCL-2/BCL-xl inhibitor chemically bonded on a 2D nanosheet. The compound can include Navitoclax deposited on 2D nanosheets of boron nitride to form a nanosphere via ?-? stacking.

Abstract: An apparatus for detecting cancer precursors in a sample by using electrodes modified with a nanocomposite that reacts with a number of cancer precursors. The modification of electrodes includes treating surfaces of the electrodes using the nanocomposite, wherein the nanocomposite includes a first metallic nanoparticle; and at least one of a second metallic nanoparticle, or carbon nanomaterial. The apparatus also includes an analytic tool for quantifying detected cancer precursors, and a display to visualize amounts of cancer precursors detected in the sample.

Abstract: A leptin detecting device is provided. The device comprises a counter electrode, a reference electrode, and a working electrode having an electroactive surface area. A Fe:Ni/C layer deposited is deposited on the counter electrode, reference electrode, and working electrode, wherein deposit of a biological tissue sample containing a concentration of leptin above a threshold level onto the Fe:Ni/C layer produces an electric current through the counter electrode, reference electrode, and working electrode. A circuit is connected to the counter electrode, reference electrode, and working electrode, wherein the circuit is configured to produce a specified waveform in response to the electric current produced by the presence of leptin above the threshold level.

Abstract: Procedures for topical treatment of melanoma and skin fibrosis include administering to a mammal in need of treatment a compound including at least one BCL-2/BCL-xl inhibitor; and at least one ionic liquid. The compound can include Navitoclax dissolved in choline octanate in a concentration from approximately 150 ug/mL to approximately 160 ug/mL.

Abstract: Procedures for targeted treatment of kidney fibrosis include administering to a subject in need of treatment of kidney fibrosis a compound including a plurality of nanoparticle including at least one BCL-2/BCL-xl inhibitor; at least one polymer comprising a member selected from the group consisting of PLGA, PEG or PVA; and at least one targeting peptide, wherein each of the plurality of nanoparticles defines a hollow shell formed by the polymer, the at least one BCL-2/BCL-xl inhibitor is located within an interior of the hollow shell, and the at least one targeting peptide is coupled to an exterior surface of the hollow shell.

Abstract: Certain embodiments are directed to compositions and related methods for oral delivery of compositions for effective administration of leptin pathway modulating agents (e.g., leptin, anti-leptin antibodies, anti-leptin receptor antibodies and the like), the composition including an ionic liquid (e.g., CAGE) or a beta-glucan composition and a leptin pathway modulator for reducing or maintaining body weight. In certain aspects the leptin pathway modulator is leptin or an anti-leptin antibody. An ionic liquid (IL) is a salt in the liquid state.

Abstract: Therapeutic compositions are disclosed which contain a therapeutic agent and a bile acid or bile acid conjugate. The compositions can be absorbed via enterohepatic circulation. The compositions include a cationic moiety and an anionic polymer, which are coupled through electrostatic interactions. The therapeutic compositions can be used for the treatment of diseases or disorders.

Abstract: Therapeutic compositions are disclosed which contain a therapeutic agent and a bile acid or bile acid conjugate. The compositions can be absorbed via enterohepatic circulation. The compositions include a cationic moiety and an anionic polymer, which are coupled through electrostatic interactions. The therapeutic compositions can be used for the treatment of diseases or disorders.

Abstract: Therapeutic compositions are disclosed which contain a therapeutic agent and a bile acid or bile acid conjugate. The compositions can be absorbed via enterohepatic circulation. The compositions include a cationic moiety and an anionic polymer, which are coupled through electrostatic interactions. The therapeutic compositions can be used for the treatment of diseases or disorders.